Positive Results for TYSABRI
Two-year data from the AFFIRM Phase III monotherapy trial presented for the first time, showed that treatment with TYSBARI (natalizumab)…
Part of the
network
network
Tag: tysabri
Elan and Biogen Suspend Marketeing of TYSABRI
Elan and Biogen Idec's ongoing safety evaluation of TYSABRI has led to a previously diagnosed case of malignant astrocytoma being…
Shares of Elan and Biogen Idec Shares Rise
Shares of Elan and Biogen Idec went up following the companies' announcement of their multiple sclerosis drug Tysabri test results.
